Germany Becomes Biosimilar HotSpot

Germany Becomes Biosimilar HotSpot

A more efficient regulatory pathway, large market and pricing pressures has made Germany the lead market for biosimilars. These are the close "generic like" replicas of biological drugs. Kalorama Information's new report details markets by country and finds the leading EU market has an advantage on other world pharmaceutical markets.


For Major Biopharma Products, Competition is Coming

For Major Biopharma Products, Competition is Coming

Biosimilars- close replicas of profitable biopharmaceutical drugs, are arriving to the U.S. market. This according to Kalorama Information's new market research study. There are dozens of companies developing similar biotherapeutics. And although they've been slow to develop in the U.S. market, there's more world development and signs of change.


IVD Can Contribute to t-mAb Effectiveness

Therapeutic monoclonal antibodies are useful therapies but in some cases they work for a period, then lose their effectiveness The role of testing in preventing therapeutic monoclonal antibodies from failing has recently received high-profile attention, with a session at AACC and in other places This blog piece by Kalorama analyst Rob Camp, PhD, looks at the role of testing.


Two Potential Drug Pipeline "Disruptors" to Watch

Two Potential Drug Pipeline "Disruptors" to Watch

Kalorama's new report isolates potential drug pipeline "disruptors," new pharmaceuticals that could change future market leadership because of their effectiveness in a given disease area. In this article we look at two of them, a drug pipeline candidate in asthma and a drug pipeline candidate in lymphoma.


Lowering Drug Prices Isn't Easy

Lowering Drug Prices Isn't Easy

Drug prices are a popular target of politicians and advocacy groups and patients themselves. Bad actors such as Mylan have given the industry a poor image. Now President Trump joined the chorus of voices saying prices are too high. But what's involved in pricing? Could steps to reduce pricing lead to worse care?


Biopharma Embraces a Microbrewery Mindset with Single-Use Bioreactors

Biopharma Embraces a Microbrewery Mindset with Single-Use Bioreactors

This blog post serves as an introduction to the bioreactors market and an impactful biopharma industry trend. More information regarding the market for single-use bioreactors can be found in Kalorama Information’s recently published The Worldwide Market for Bioreactors.

Fermentation is serious business, whether its in the biopharmaceuticals or beverage industry. Similarities in the production processes of biosimilar drugs and beers can be spotted readily, but the comparison usually ends there ...


Biopharmaceutical Boom Drives Cell Culture Market Growth

Biopharmaceutical Boom Drives Cell Culture Market Growth

Biopharmaceuticals have become a primary growth driver for not only pharmaceutical companies, but also upstream bioprocessing product suppliers. The production of vaccines, hormones, blood factors, thrombolytics, interferons, monoclonal antibodies and therapeutic enzymes requires cell culturing and the voluminous supply of culture media, sera, and reagents. The market for cell cultures is expected to grow rapidly alongside biopharmaceuticals and with significant evolution in culture technology. ...